Tags : Novel Fibroblast Targets


Janssen Signs an Option and License Agreement with Mestag to

Shots: Mestag to receive option fees, milestones, royalties and will deploy its specialist fibroblast sub-population biology platform and state-of-the-art data analytics to identify novel therapeutic targets Janssen to get an option to exclusive license to develop and commercialize therapies directed against up to two targets emerges from the collaboration Apart from this collaboration, Mestag will […]Read More